Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Highlights

Highlights In This Issue July 2018 Volume 154, Number 7 JAMA Dermatology Pages 745-856 Opinion Hyaluronidase Used to Remove HA Filler 765 Hyaluronic acid (HA) fillers are essential tools in the field of noninvasive cosmetic derma- Viewpoint tology. One attractive feature of HA fillers is their reversibility in response to hyaluronidase 755 Reevaluating Mohs Surgery injections. Most of the anecdotal literature on hyaluronidase use for the management of Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma filler complications focuses on relatively high-dose injections. In this randomized clinical trial, HK Steinman and Coauthors Alam et al demonstrate that small unit doses of hyaluronidase allowed removal of minute 757 Geriatric Dermatology— quantities of filler without removing the entire implant. Clinicians may thus fine-tune filler- A Framework for Caring for Older Patients associated contour without complete removal of HA filler from the treatment site. With Skin Disease Editorial 763 E Linos and Coauthors Continuing Medical Education jamanetwork.com/learning Clinical Review & Education Topical Rapamycin for Facial Angiofibromas 773 JAMA Dermatology Facial angiofibromas occur in approximately 75% of individuals with tuberous sclerosis com- Clinicopathological Challenge plex (TSC). Rapamycin is an mTOR inhibitor that has demonstrated positive results for TSC- related conditions, but oral mTOR http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Highlights

JAMA Dermatology , Volume 154 (7) – Jul 1, 2018
Download PDF
1 page
Read Article

Highlights

Abstract

In This Issue July 2018 Volume 154, Number 7 JAMA Dermatology Pages 745-856 Opinion Hyaluronidase Used to Remove HA Filler 765 Hyaluronic acid (HA) fillers are essential tools in the field of noninvasive cosmetic derma- Viewpoint tology. One attractive feature of HA fillers is their reversibility in response to hyaluronidase 755 Reevaluating Mohs Surgery injections. Most of the anecdotal literature on hyaluronidase use for the management of Appropriate Use Criteria for Primary Superficial...
Loading next page...
 
/lp/american-medical-association/highlights-BIUDqPtHLu
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2017.3843
Publisher site
See Article on Publisher Site

Abstract

In This Issue July 2018 Volume 154, Number 7 JAMA Dermatology Pages 745-856 Opinion Hyaluronidase Used to Remove HA Filler 765 Hyaluronic acid (HA) fillers are essential tools in the field of noninvasive cosmetic derma- Viewpoint tology. One attractive feature of HA fillers is their reversibility in response to hyaluronidase 755 Reevaluating Mohs Surgery injections. Most of the anecdotal literature on hyaluronidase use for the management of Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma filler complications focuses on relatively high-dose injections. In this randomized clinical trial, HK Steinman and Coauthors Alam et al demonstrate that small unit doses of hyaluronidase allowed removal of minute 757 Geriatric Dermatology— quantities of filler without removing the entire implant. Clinicians may thus fine-tune filler- A Framework for Caring for Older Patients associated contour without complete removal of HA filler from the treatment site. With Skin Disease Editorial 763 E Linos and Coauthors Continuing Medical Education jamanetwork.com/learning Clinical Review & Education Topical Rapamycin for Facial Angiofibromas 773 JAMA Dermatology Facial angiofibromas occur in approximately 75% of individuals with tuberous sclerosis com- Clinicopathological Challenge plex (TSC). Rapamycin is an mTOR inhibitor that has demonstrated positive results for TSC- related conditions, but oral mTOR

Journal

JAMA Dermatology – American Medical Association

Published: Jul 1, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$499/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

Sign up
for free
Start 14 day
Free Trial